Archives

As we see time and time again, health insurance providers and pharmacy benefit managers (PBMs) are beginning to shift a

Here’s a link to the channel EVERY CELL A UNIVERSE The aim of the channel is to share that fascinating

The Biotechnology Innovation Organization, a national trade association representing the bioscience industries, conducted a study titled “Investment, …

Liquidia Technologies focuses on the small. Its method of producing nano-scale particles improves how a drug reaches its target in

Opioid abuse and addiction in America has reached epidemic heights. As a nation, we’re spending more than $500 billion annually

If you’re running a privately held biotech, the time to go public is now. Clinical data already in hand or

[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: H2020-LC-SC3-2018-2019-2020Pillar: Societal ChallengesOpening Date: Deadline: Thu, 23 Aug 2018 17:00:00 (Brussels local time)Modification Date: Fri, 29 Jun

An experimental Acceleron drug for a blood disorder has hit the main goals of a pivotal study, and the company

Alan Kimura has been appointed chief medical officer of Cambridge, MA-based Enzyvant. Before joining Enzyvant, Kimura was chief medical officer

[Source: Research & Innovation] A huge amount of biological knowledge and clinical data is incrementally generated, but this wealth of